AnaptysBio AAQS

Mitä AnaptysBio tekee? AnaptysBio Inc is a biopharmaceutical company founded in 2005 and headquartered in San Diego, California. The company focuses on researching, developing, and marketing novel therapeutic antibodies for the treatment of autoimmune diseases, inflammation, and cancer. AnaptysBio has a unique business model that aims to make antibody development more efficient and cost-effective. Instead of relying on traditional methods like the hybridoma technique, the company uses its proprietary SHM-XEL technology to isolate and identify human antibodies directly from B cells. This approach allows AnaptysBio to quickly find, test, and optimize high-quality antibody candidates, resulting in significantly shorter development times and lower costs. The company has two main divisions. The first division focuses on the development of antibodies for the treatment of autoimmune diseases and inflammation. In this division, AnaptysBio has several promising antibody candidates in its pipeline, including ANB020, an antibody against the immune system protein IL-33, being developed for the treatment of asthma and other allergic diseases. ANB019, an antibody against the immune system protein IL-36R, being developed for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis, is another promising candidate. The second division of AnaptysBio focuses on the development of antibodies for the treatment of cancer. Here, the company has formed a promising partnership with TESARO, a leading cancer therapy company. Together, they are developing an antibody called TSR-042 that targets the immune system protein PD-1 and is used for the treatment of various cancers such as lung cancer and bladder cancer. AnaptysBio also has several products on the market that are based on its proprietary SHM-XEL technology. These include Simponi (Golimumab), an antibody used for rheumatoid arthritis, Crohn's disease, and psoriasis, for which AnaptysBio developed the technology in partnership with Janssen Biotech. Over the years, AnaptysBio has received several significant awards and recognition for its innovative antibody development platforms and technologies. In 2017, the company was included in the Deloitte Technology Fast 500 list and received the Frost & Sullivan Technology Innovation Award for its SHM-XEL technology. Overall, AnaptysBio is an innovative biopharmaceutical company with a unique business model and a promising pipeline of antibody candidates for the treatment of autoimmune diseases, inflammation, and cancer. Through its proprietary technology and partnerships with other companies, AnaptysBio remains well-positioned to continue providing innovative therapeutic solutions for patients. AnaptysBio on yksi Eurpooliin suosituimmista yhtiöistä.